Two Sigma Advisers
STOK icon

Two Sigma Advisers’s Stoke Therapeutics STOK Stock Holding History

Two Sigma Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,500
Closed -$178K – 2524
2024
Q3 		$178K Sell
14,500
-5,200
-26% -$73.7K ﹤0.01% 2097
2024
Q2 		$266K Buy
+19,700
New +$266K ﹤0.01% 2121
2024
Q1 		– Sell
-11,000
Closed -$57.9K – 2632
2023
Q4 		$57.9K Sell
11,000
-2,800
-20% -$12K ﹤0.01% 2390
2023
Q3 		$54.4K Buy
+13,800
New +$90.7K ﹤0.01% 2271
2023
Q1 		– Sell
-36,600
Closed -$338K – 2742
2022
Q4 		$338K Buy
36,600
+11,000
+43% +$114K ﹤0.01% 2027
2022
Q3 		$329K Buy
25,600
+7,000
+38% +$112K ﹤0.01% 2008
2022
Q2 		$246K Sell
18,600
-100
-0.5% -$1.52K ﹤0.01% 2195
2022
Q1 		$394K Sell
18,700
-21,300
-53% -$427K ﹤0.01% 2103
2021
Q4 		$960K Sell
40,000
-41,100
-51% -$981K ﹤0.01% 1576
2021
Q3 		$2.06M Buy
81,100
+33,500
+70% +$934K 0.01% 1232
2021
Q2 		$1.6M Buy
47,600
+23,000
+93% +$813K ﹤0.01% 1413
2021
Q1 		$955K Buy
+24,600
New +$1.4M ﹤0.01% 1673

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Two Sigma Advisers's STOK Position: Q4 2024 in Review

Two Sigma Advisers sold out of Stoke Therapeutics (STOK) in Q4 2024, closing a stake of 14,500 shares — an estimated $178K sold.

Two Sigma Advisers first reported a position in STOK in Q1 2021 and held it in 12 quarters. The position peaked at $2.06M in Q3 2021. 130 funds tracked by Wall St. Rank hold STOK as of Q4 2024.

  • Two Sigma Advisers reported no remaining Stoke Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 14,500 Stoke Therapeutics shares in Q4 2024, an estimated $178K.
  • Two Sigma Advisers first reported a position in Stoke Therapeutics in Q1 2021 and held it in 12 quarters.
  • Two Sigma Advisers's Stoke Therapeutics position peaked at $2.06M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.